GlassScriptPhysician profile
Thomas A Loesevitz
NPI 1558755108
$4,643.32
in general payments reported to CMS, 2019-2025
38 companies · $1,416 in 2025
The $1,416 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $138 · 2021: $28.06 · 2022: $459 · 2023: $958 · 2024: $1,101 · 2025: $1,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,475.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $623.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $564.86 | 2022-2025 | |
| Amgen INC. | $383.74 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $372.24 | 2019-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Pfizer INC. | $317.65 | 2019-2025 | |
| Lilly USA, LLC | $306.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $219.39 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $160.26 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $154.23 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $114.24 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $99.77 | 2020-2025 | |
| Idorsia Pharmaceuticals US INC | $97.83 | 2023-2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.17 | 2019-2020 | |
| Exact Sciences Corporation | $80.98 | 2025 | Cologuard Collection Kit |
| Helsinn Therapeutics (U.S.), INC. | $77.52 | 2019 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Loesevitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.